Long-term clinical outcome in meige syndrome treated with internal pallidum deep brain stimulation

René Reese1, Doreen Gruber, Thomas Schoenecker

  • 1Department of Neurosurgery, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.

Insights

Deep brain stimulation (DBS) of the globus pallidus internus effectively treats Meige syndrome, a type of dystonia. Long-term results show sustained improvement in symptoms for up to six years.

Area of Science:

  • Neurology
  • Neurosurgery
  • Movement Disorders

Background:

  • Deep brain stimulation (DBS) of the globus pallidus internus (GPi) is established for dystonia treatment.
  • Orofacial dystonia, including Meige syndrome, shows less improvement with GPi DBS compared to other forms.
  • Preliminary studies suggest short-term benefits of GPi DBS for severe Meige syndrome.

Purpose of the Study:

  • To evaluate the long-term efficacy and safety of bilateral GPi DBS in patients with Meige syndrome.
  • To extend preliminary findings by assessing outcomes over an extended follow-up period.

Main Methods:

  • A multicenter case series involving 12 patients with Meige syndrome.
  • Retrospective assessment of dystonia severity using video documentation and standardized rating scales (Burke-Fahn-Marsden Dystonia Rating Scale, Blepharospasm Movement Scale, Abnormal Involuntary Movement Scale).
  • Follow-up extended up to 78 months, with both short-term and long-term outcome analysis.

Main Results:

  • Significant mean improvement in dystonia severity of 45% at short-term and 53% at long-term follow-up (P < 0.001).
  • Sustained improvements observed in specific symptom subscores including eyes (up to 47%), mouth (up to 56%), and speech/swallowing (up to 64%).
  • Significant reductions in blepharospasm and abnormal involuntary movements were maintained long-term.

Conclusions:

  • Bilateral GPi DBS is a safe and highly effective long-term therapy for Meige syndrome.
  • The therapeutic benefits of GPi DBS for Meige syndrome are preserved for up to 6 years.
  • This study provides the first long-term follow-up data in a substantial cohort, supporting GPi DBS as a viable treatment option.

Related Concept Videos